WaveMan
WaveMan · Company
BMRA · Biomerica Inc
> Search tickers & screens ⌘K
LIVE
← All companies

BMRA Biomerica (BMRA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000073290
Quote by TradingView
Cluster · 5 insidersActivist 13DC-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter

What the filings say about BMRA

Insiders, 180 days
+$158.0K net bought
5 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 10.0% of the class

Biomerica insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BIOMERICA INC insiders bought a net $158.0K of stock across 18 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
BARBIERI ALLEN
Executive Vice Chairman
BUY
2026-08-27 SECtraded 2026-08-26
20,000
$32.0K
-20.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 27, 2023.
  • The trade is 27.2% of the 73,542 shares held after it.
  • 4 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice Chairman BARBIERI ALLEN bought about $32.0K of BMRA on Aug 26, 2026; 4 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Irani Zackary S.
Chief Executive Officer
BUY
2026-08-27 SECtraded 2026-08-26
31,250
$50.0K
-20.1%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on May 25, 2023.
  • +3.2% median (-9.2% mean) 90-day return after 11 previous buys.
  • The trade is 12.9% of the 242,570 shares held after it.
  • 4 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Irani Zackary S. bought about $50.0K of BMRA on Aug 26, 2026; 4 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
MOATAZEDI DAVID
Director
BUY
2026-08-27 SECtraded 2026-08-26
10,000
$16.0K
-20.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 24.6% of the 40,625 shares held after it.
  • 4 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MOATAZEDI DAVID bought about $16.0K of BMRA on Aug 26, 2026; 4 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Chin Eric
Director
BUY
2026-08-27 SECtraded 2026-08-26
6,250
$10.0K
-20.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.1% of the 38,750 shares held after it.
  • 4 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Chin Eric bought about $10.0K of BMRA on Aug 26, 2026; 4 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Gary M. Huff
Director
BUY
2026-08-27 SECtraded 2026-08-20
31,250
$50.0K
-20.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 61.0% of the 51,250 shares held after it.
  • 4 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gary M. Huff bought about $50.0K of BMRA on Aug 20, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 13 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$158.0K over 180 days
+$158.0K over 90 days
more than 79% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
-16.2% year over year
below 68% of Pharma & Biotech
Margin
-84.8% net margin
below 56% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 85% of Pharma & Biotech
The situation: each line is one rule over one dataset
5 insiders independently bought a net $158.0K while the stock fell 22% over six months, with no planned sales queued.
BRC Group Holdings, Inc. disclosed a 5%+ stake (10.03%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BMRA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-41.2%12M
-49%-32%-15%+2%2025-102025-122026-022026-042026-062026-082026-10 2026-08-20 · Gary M. Huff bought $50.0K2026-08-26 · Irani Zackary S. bought $50.0K2026-08-26 · BARBIERI ALLEN bought $32.0K2026-08-26 · MOATAZEDI DAVID bought $16.0K2026-08-26 · Chin Eric bought $10.0K2026-08-28 · BRC Group Holdings, Inc. filed a 5%+ stake (10.03%)2026-08-28 · B. Riley Principal Capital, LLC filed a 5%+ stake (10.03%)2026-08-28 · Bryant R. Riley filed a 5%+ stake (10.03%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BMRA: institutional holders (13F)

13F holdings, latest reported quarter
GEODE CAPITAL MANAGEMENT, LLC
24,347 sh
$42.9K
BlackRock, Inc.
18,636 sh
$32.8K
VANGUARD CAPITAL MANAGEMENT LLC
14,514 sh
$25.5K
JANE STREET GROUP, LLC
12,640 sh
$22.2K
LPL Financial LLC
10,849 sh
$19.1K

Congress trades in BMRA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
BRC Group Holdings, Inc.
Activist 13D · 2026-08-28
10.03%
B. Riley Principal Capital, LLC
Activist 13D · 2026-08-28
10.03%
Bryant R. Riley
Activist 13D · 2026-08-28
10.03%

BMRA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BMRA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$104.4K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$25.5K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.5K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$4.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Zackary Irani
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$285.4K
$241.2K
$276.0K
-78%
n/a
2024
$201.0K
$177.7K
$219.8K
-72%
n/a
2023
$360.1K
$199.8K
$314.8K
-58%
n/a
2022
$141.2K
-$108.4K
$174.0K
-61%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $158.0K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BMRA financials

Revenue growth
-16.2%
XBRL, annual
Net margin
-84.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.3M
four quarters, 2025-09-01 to 2026-08-31
Net margin, TTM
-115.5%
net income over revenue, 2025-09-01 to 2026-08-31
Free cash flow, TTM
-$4.0M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-113.8%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets
-67.1%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-104.5%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-50.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-052025-052024-052023-05
Revenue$4.5M$5.3M$5.4M$5.3M
Gross profit$362.0K$498.0K$611.0K$446.0K
Operating income-$5.3M-$5.1M-$6.4M-$7.2M
Net income-$3.8M-$5.0M-$6.0M-$7.1M
EPS (diluted)-1.30-2.16-2.84-0.50
Operating cash flow-$3.4M-$3.8M-$5.4M-$5.5M
Cash$1.3M$2.4M$4.2M$9.7M
SEC XBRL, fiscal years, as known on 2026-10-28

BMRA Stock Sonar score 5/7 axes

Find similar shapesCompare

BMRA ranks highest on insider conviction (88th percentile) and risk and compliance (52nd), and lowest on institutional and government (18th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
30
Inputs
  • Return on equity-113.8% · 30 pct, sector of 545
  • Return on assets-67.1% · 36 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-104.5% · 24 pct, sector of 576
Growth
32
Inputs
  • Revenue growth, YoY-16.2% · 32 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
88
Inputs
  • Net Form 4 buying (codes P and S), 180d$158K · 78 pct, sector of 429
  • Insider buyers, 180d5 · 97 pct, sector of 438
Institutional and government
18
Inputs
  • Funds adding, latest quarter10 · 18 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
52
Inputs
  • Short interest, % of float+0.2% · 89 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+20.5% · 15 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BMRA filings, in plain words

Are Biomerica insiders buying or selling BMRA?

In the 180 days to 2026-10-28, Biomerica insiders were net buyers, a net $158.0K across purchases and sales reported on Form 4, by 5 buyers.

Read the full summary

In the 180 days to 2026-10-28, Biomerica insiders were net buyers of BMRA, a net $158.0K across purchases and sales reported on Form 4 by 5 buyers. 5 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 10.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies